Skip to main content

Silas Day

Authored Items
Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia
Amany R. Keruakous, MD, Sarah A. Schmidt, PharmD, Marcus T. Autry, PharmD, Julia Ye, PharmD Candidate, Phoi Nguyen, PharmD Candidate, Silas Day
JHOP - February 2021 Vol 11, No 1 in Case Reports, Dose Escalation/Reduction, Leukemia
Last modified: February 24, 2021